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Background: Syphilis is an important sexually transmitted infection (STI) with serious public health consequences.
Among men who have sex with men (MSM) in Lima, the prevalence and incidence are extraordinarily high. Current
syndromic approaches, however, fail to identify asymptomatic cases, and in settings where large proportions of
individuals test positive again after treatment, it is frequently difficult to distinguish treatment failure from re-
infection. Thus, new approaches are needed to improve treatment strategies and public health control efforts.
Methods/Design: Study participants will undergo baseline testing for syphilis infection along with a behavioral
survey covering demographics, sexual behavior, drug and alcohol abuse and health-care seeking behavior. The
cohort will be followed for 18 months at three-month intervals. Blood and earlobe scrapings will also be collected
for T. pallidum DNA testing, to create molecular markers for subtyping. We will also perform cytokine testing on
collected samples in order to create host immunologic profiles associated with recurrence, re-infection, treatment
failure and success.
Discussion: Advances in social epidemiology, molecular typing and characterization of host immune responses will
offer promise in developing new understandings of syphilis management. We will share our findings with the
Peruvian Ministry of Health and other public health organizations, to identify new approaches of case detection and
successful treatment.
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Syphilis remains an important sexually transmitted infec-
tion (STI) with grave medical and public health conse-
quences if left untreated. It is caused by the bacterium
Treponema pallidum (T. pallidum) and is the leading
cause of preventable infant mortality, surpassing HIV in-
fection globally [1]. The risk of acquiring and transmitting
HIV infection is increased in the presence of syphilitic
ulcers [2,3]. Between 10 and 12 million new infections of
syphilis occur worldwide annually, including an estimated
2–3 million cases in Latin America, [4] mostly among* Correspondence: carlos.caceres@upch.pe
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reproduction in any medium, provided the orhigh-risk populations including sex workers, men who
have sex with men (MSM) and male-to-female transgender
women (TW) [5].
Despite existing prevention and control programs, syph-
ilis infection remains an important public health problem
in Lima, Peru, concentrated largely among MSM and TW
[6-8]. A study of 1,056 high-risk MSM/TW found a life-
time prevalence of 21.6% and an incidence rate of 8.4
cases/100 person-years (95% CI: 6.7-7.1) [7]. A related
study found that among HIV-antibody positive MSM/
TW, the prevalence of active, untreated disease was 21%
and a lifetime history of syphilis infection was 35.5% [9].
High rates of syphilis infection among MSM/TW have im-
plications for the broader population in Peru, as previous
studies have found higher prevalence of syphilis amongtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Our study invokes the classic disease triangle through
a) measurement of cytokines and immune responses (HOST),
DNA sequencing of T. pallidum (PATHOGEN) and our survey of
social determinants and sexual risk behaviors to elucidate
social-sexual networks (ENVIRONMENT). Interplay between these
domains will inform new strategies for syphilis control efforts.
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whose male partners had sex with men [11,12].
In Peru and other Latin American countries, the
current syndromic approach to syphilis management,
which relies on diagnosis and treatment based on rec-
ognition of ulcerative lesions, has proven inadequate in
controlling the syphilis epidemic, and thus, new ap-
proaches are warranted. Syphilis control efforts are fre-
quently complicated by treatment failure and high rates
of repeat infection—up to 43% in one study in Peru,
[13] and failure to detect asymptomatic infections [14].
Often, it is not clear whether a new diagnosis repre-
sents past treatment failure, re-infection or identifica-
tion of a previously asymptomatic infection, and thus,
improved case-finding and diagnostic strategies are ur-
gently needed.
In order to characterize the determinants of the
current syphilis epidemic among MSM/TW in Peru, and
to better inform syphilis treatment and control strategies
worldwide, it is critical to study various aspects of the
pathogen, host, and environment among syphilis cases.
Here we describe an observational study focused on
MSM/TW who were diagnosed with, or are at high risk
of syphilis, that will take place over a period of 5 years
(2013–2017) in Lima, Peru. We will first characterize
the prevalence and incidence of syphilis among MSM/
TW. Next, through ascertainment of treatment status,
host immune response, and pathogen genotype analysis,
we will classify cases as reinfection, persistent infection/
treatment failure, or recurrence based on incomplete
treatment. Data will be collected on diagnosis/treatment
history, sexual behavior, and in-depth immunological
and molecular biologic aspects of the pathogen. To im-
prove the population-specific understanding of syphilis,
molecular typing will provide broad information on the
T. pallidum bacteria encountered to distinguish between
re-infection with a new strain, antimicrobial resistance
or persistence of original infection. Through behavioral,
diagnostic, molecular and immunological research, our
study offers potential to develop new approaches that
may inform strategies for improving current syphilis
control strategies (Figure 1).
Methods/Design
Overview
Our group, led by a collaboration between experienced
senior investigators from Universidad Peruana Cayetano
Heredia (UPCH) and University of California, Los Angeles
(UCLA), Epicentro and Barton Health Center will study a
cohort of high-risk MSM/TW. The cohort is expected to
have a baseline prevalence of 10% for untreated syphilis,
an annual incident rate of 5–10%, and treatment failure
rates or re-infection of 25–50% [7,14]. Studying syphilis in
this population provides several opportunities: 1) readyidentification of primary and secondary stages of syphilis,
making clinical specimens of T. pallidum available for
molecular characterization; 2) description of outcomes in-
cluding treatment success, failure or re-infection in a short
observation period; and 3) development of a cohort to
allow frequent monitoring of behavioral, clinical and im-
munological parameters to define predictors of infection,
treatment response, and re-infection. The study protocol
has been approved by the institutional review boards at
UPCH, Barton Health Center and UCLA.
Our cohort will consist of 400 MSM/TW meeting high
risk criteria for syphilis, who will be assessed at baseline
and then at 3, 6, 9, 12, 15 and 18 months. Study visits
will entail behavioral surveys and testing for syphilis and
other STIs. We will also obtain samples for cytokine
measurements and to test for T. pallidum DNA, as
detailed below, in order to understand molecular and
immune profiles associated with markers of treatment
success and failure.
Participant recruitment and retention
Between 40–60 participants will be recruited each
month from two clinical sites in Lima, including a public
reference STI clinic (Barton Health Center) specialized
in at-risk populations including MSM/TW, and a Gay
Men’s community center (Epicentro) located in a metro-
politan area of Lima. Both locations are well-recognized
and reachable by the target population, particularly
lower-middle income individuals. We will screen up to
1,000 patients in order to recruit a high-risk cohort of
400 people. We project that Barton Health Center will
account for 70% of the recruited patients, with 30%
recruited at Epicentro.
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the two-year study if they meet at least three of the fol-
lowing high-risk criteria: i) having had a positive syphilis
test in the past 2 years, ii) having HIV infection, iii) hav-
ing any syndromic ulcer-related STI (i.e. HSV-2, syphilis
or genital ulcerative disease) at the time of screening; iv)
having been diagnosed with an STI in the past 6 months);
v) having more than 5 years of sexual activity; vi) having
more than 5 sex partners in the past 3 months, or vii)
having more than 5 occurrences of unprotected anal sex
in the past 6 months.
To facilitate participant retention and follow-up care, we
will utilize cell phone text messages (SMS), phone calls,
e-mail and Internet chat to provide regular follow-up
reminders. Several studies have shown that text reminders,
provided on a weekly basis, increase cohort retention and
follow-up [15,16]. The use of mobile phones and internet
has increased dramatically in Peru in the last several years
and is a preferred way of communication, allowing for
novel methods for STI management, case-finding, treat-
ment follow-up and cohort retention [17].
Study visits will be held within established clinical set-
tings, which will provide safe and private spaces for
conducting surveys, obtaining samples and providing
clinical care. At the time of enrollment, participants will
meet individually with a staff member to review all study
procedures, including the benefits and risks of participa-
tion, the option to discontinue participation at any time
without penalty, and means of contacting the investi-
gator and the local study institutional review board if
questions about participation in the study arise. Signed
informed consent will be obtained from all participants
prior to any study activities. Study forms will include de-
identified numbers, and data from all encounters will be
maintained in locked areas. Study information sheets
with personally identifying contact information will be
stored in separate locked areas, with linkage information
only available to the study investigators.
Data collection and laboratory testing
Demographic characteristics, sexual and risk behavior,
health/health care seeking behavior, history of current/Table 1 Peruvian syphilis treatment guidelines (non-pregnan
Treatment
Primary Penicillin G 2.4 million Units IM, single dose
Secondary Penicillin G 2.4 million Units IM, single dose
Early latent Penicillin G 2.4 million Units IM, single dose
Late latent Penicillin G 2.4 million Units IM, 3 weekly doses
Tertiary Penicillin G 2.4 million Units IM, 3 weekly doses
Neurosyphilis Penicillin G 4 million units IV q4h × 10–14 days
1Tetracycline 500 mg po qid may be substituted for Doxycycline.past syphilis infection (including treatment), alcohol use
and substance abuse history will be assessed at baseline
and three month intervals. Follow-up risk behavior assess-
ments will elicit self-reported behavior for the last three
months only. Participants will receive pre-test counseling
along with a rapid HIV test (with EIA and Western Blot
confirmation). Participants diagnosed with HIV infection
will be referred to the Peruvian National HIV Treatment
Program. Syphilis testing will be performed via sampling
of whole blood, lesion swabs (if present) and ear lobe
scraping (when rapid syphilis testing is positive and/or
lesions are present) [18,19].
We will utilize a highly accurate point-of-care specific
test to identify antibody-positive patients [20]. Syphilis-
specific T. pallidum antibody tests are more sensitive and
specific for syphilis infection than conventional non-
treponemal tests used in routine clinical practice, particu-
larly in early infection [21]. Rapid Plasma Reagin (RPR)
tests will be used to establish specific titers followed by
confirmation through T. pallidum-Particle Agglutination
test (TPPA) using a cutoff value of ≥ 1:80. Treatment for
syphilis will be offered on-site for detected cases, in line
with Peruvian National STI Treatment Guidelines, [22]
(see Table 1). Individuals with neurologic symptoms will
be referred for additional diagnostics and care.
We will collect three types of samples: lesion exudates
(if lesions are found), blood samples and ear lobe scrap-
ings for T. pallidum DNA detection, previously unmeas-
ured together in any cohort study. Individuals who test
positive for Treponema pallidum DNA by these methods
will be treated in the same manner as the RPR/TPPA al-
gorithm described above. In quarterly follow-up visits,
individuals who were not reactive to rapid syphilis tests
at recruitment will be assessed for new syphilis infec-
tions with repeat serologic tests; those who were diag-
nosed with syphilis at recruitment or subsequent visits
will be assessed for cure, or re-infection/persistence of
seroreactivity.
Sample size and power calculations
Based on our research experience we anticipate screening
about 600 potential participants in order to reach 400t)
Alternative
Doxycyline 100 mg po bid × 2 weeks1
Doxycyline 100 mg po bid × 2 weeks1
Doxycyline 100 mg po bid × 2 weeks1
Doxycyline 100 mg po bid × 4 weeks1
Doxycyline 100 mg po bid × 4 weeks1
Penicillin Procaine 2.4 million units IM daily × 10–14 days
with Probenecid 500 mg po four times daily × 10–14 days
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ments. A sample size of 400 will produce a two-sided
95% confidence interval with a width equal to 8 units
when the actual baseline population syphilis prevalence
equals 20% [14]. With a potential attrition rate as ex-
treme as 18% over 18 months from our previous re-
search experience, [16] the least expected final sample
size for the cohort analysis will be 328. Extrapolating
a previously reported incidence rate of 8.4 per 100
person-years in similar high-risk Peruvian MSM popu-
lations [7] to our final sample of 328, and assuming
homogenous occurrence of incident syphilis cases dur-
ing the proposed 18 months of follow-up, we expect 41
total incident cases and a cumulative incidence of
12.5%, with a 95% confidence interval width equal to
7%. All sample size estimations were computed using
NCSS/PASS 2011 software (Kaysville, UT, 2011).
Statistical analyses
Frequency distributions will be tabulated for all variables,
performing range checks and cross-validations, and indi-
vidually evaluating all data points with measurements three
standard deviations above their mean. Missing or errone-
ous data will be coded as such and frequencies of unusable
data will be calculated for every variable to determine if
the frequency was unusually high and affected the validity
of the data. All outcomes will be calculated at the individ-
ual level: 1) number of prevalent syphilis cases in the ini-
tially screened population, 2) number of incident syphilis
cases during the study period, and 3) number of persistent
syphilis infections based on RPR titers during the study
period. Observation time will be adjusted for subjects who
do not complete the study follow-up.
New cases and individuals who received treatment at
baseline but who have a 4-fold titer increase at follow-
up visits will be considered incident cases. The rate will
be expressed as incidence density, calculated with the
total number of incident STIs and total observation
time. In addition to the incidence and prevalence of
syphilis infection, we will also calculate the number of
persistent syphilis infections as defined by participants
with prevalent or incident cases of syphilis whose RPR
titers do not decrease adequately over time.
Bivariate and multivariate analyses will be conducted
to determine socio-behavioral and biological variables
associated with all three outcomes of interest listed
above. For the prevalent syphilis outcome, prevalence ra-
tios will be calculated to avoid overestimation of mea-
sures of association which would result from logistic
regression [23]. For the additional outcomes (incident
and persistent syphilis), incidence rate ratios with confi-
dence intervals will be calculated, and Cox regression
will be used for the multivariate models. A sequential
approach using nested models will be used to determinethe statistical significance of the variables, using the like-
lihood ratio test to assess the strength of the evidence
against the null hypothesis of no-effect for each variable.
Molecular analysis
Detection of T. pallidum DNA has been facilitated by
improved methods of collection and amplification
[18,19,24-27]. To optimize the detection of T. pallidum
DNA in our study, we will swab any suspicious clinical
lesions, collect whole blood samples by venipuncture
and from ear lobe scrapings, and conduct routine ano-
scopy and dark-field examination of mucosal lesions
among participants at every three-month visit. While
clinical lesions like anogenital ulcers provide the best
source of T. pallidum DNA, newer work has shown that
detection of T. pallidum DNA in whole blood from ear
lobe scrapings is more sensitive than venous whole
blood when no lesions are present[18,19]. In prior stud-
ies, T. pallidum detection ranged from 70–90% in le-
sions of primary and secondary syphilis and 30–50% in
whole blood collected by venipuncture. In latent syphilis
infection, Castro et al. were able to demonstrate T.
pallidum DNA from 56–76% of whole blood specimens
collected by ear lobe scraping [19]. From these samples,
we will use conventional PCR to amplify the gene region
of polA, the most common target of PCR amplification
for T. pallidum DNA [28]. As a control for specimen
adequacy, DNA extraction and the detection of PCR
inhibitors, we will also amplify human β–globin gene
in all clinical specimens.
In addition to improvements in DNA extraction, the
molecular characterization of T. pallidum has evolved in
recent years to newer, more discriminatory methods which
use multiple genes and targets. Molecular subtyping has
also been performed on T. pallidum specimens, allowing
researchers to link sub-types to specific transmission net-
works or clinical outcomes, [29] including neurosyphilis.
As the treatment for neurosyphilis differs from the treat-
ment of genital ulcer disease or clinical syphilis, the
characterization of T. pallidum subtype could influence
syphilis diagnosis and management in Peru.
The development of molecular markers of cure is also
an evolving and promising area of research. In Castro’s
study of T. pallidum DNA collected via sera, whole blood,
plasma or earlobe scrapings, no patients with treated
syphilis (n = 18) had detectable T. pallidum DNA, thus
providing one of the first demonstrations of a microbio-
logical marker for treatment success of latent syphilis in
humans [19]. Blood specimens collected from ear lobe
scrapings have also been used to demonstrate microbio-
logic clearance among patients treated for latent syphilis
[14]. We will therefore combine conventional serological
markers with clinical response to therapy and micro-
biological clearance as determined by the presence or
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logical marker of treatment success, we hope to identify
serum cytokine profiles associated with microbiologic
cure. As serum markers are more readily collected and
measured than ear lobe blood specimens, this avenue of
research could provide a major advance in syphilis thera-
peutic monitoring and cure.
Antimicrobial resistance
Our PCR–based assay will also be used to screen for the
23S rRNA gene mutation to macrolides. This point mu-
tation is important in altering susceptibility to treatment
with azithromycin, [24] resulting in high incidence of
clinical treatment failure. There have been no studies of
azithromycin resistance to T. pallidum in Peru, and
while not widely used, epidemiologic surveillance is of
substantial public health importance to inform and up-
date current national treatment guidelines, particularly
for individuals who are penicillin-allergic or in whom
tetracyclines are contraindicated (e.g. children and preg-
nant women). Knowledge from antimicrobial resistance
classification will further help determine whether treat-
ment failures are due to infection with an antimicrobial
resistant pathogen, non-adherence, or host immune sys-
tem failure.
Immunologic basis of syphilis infection
Measurement of cytokine activity in clinical blood speci-
mens has been revolutionized with the advent of
Luminex technology. Knudsen et al. recently showed
that early stage infection was associated with an increase
in IL-10 whereas IL-10 and TNF-a both decreased after
treatment of syphilis [30]. These clinical data build on
prior work showing how Th1 and Th2 cytokine patterns
corresponded to disease progression, [31] as IL-10 has
further been postulated to play an important role in
dampening the host’s response to infection [32]. Simi-
larly, in an animal model of another spirochetal infec-
tion, Borrelia spp, IL-10 deficiency was associated with
rapid innate immune clearance of infection [33]. Thus,
persistent expression of IL-10 in humans might be asso-
ciated with treatment failure and/or re-infection.
In order to identify potential markers for cure, we will
determine serum cytokine profiles of patients before,
during and after syphilis infection and associate these
profiles with various categories of patient outcomes, in-
cluding treatment success/failure and re-infection. Add-
itionally, we will compare these profiles with profiles
from uninfected patients as a control group, to identify
predictors of infection and response to therapy. We
hypothesize that in early infection, we will observe a
dominant Th2 response (increased IL-10) that evolves to
an effective Th1 response (IL-2, IFN-gamma, TNF-alpha)
associated with the clearance of infection.In addition, cytokines related to Th1 immunity will be
assessed in conjunction with serologic RPR titers, pres-
ence of lesions if any, re-infection, serological persistence
and T. pallidum sub-species. To inform the development
of new diagnostics, we will build a predictive cytokine
model associated with new and persistent infection with
syphilis. Given the number of cytokines of interest, we will
apply Sidak’s correction for multiple comparisons to ad-
just p-values defining significance. We will then perform
bivariate and multivariate analyses, using likelihood ratio
testing to determine inclusion variables. In addition,
receiver-operating characteristic (ROC) and calibration
curves will be used to determine the accuracy of the mo-
del. Depending on the sample size, the model may be built
on half of the data and reproduced on the remaining half
to explore transportability [34].
Discussion
We anticipate that the benefits of study participation will
outweigh risks, including loss of confidentiality and priv-
acy of clinical information. A number of mechanisms
will be enforced to minimize these risks: In turn, partici-
pants will benefit from treatment of newly-diagnosed
STIs, along with increased awareness and education per-
tinent to STI prevention. New understandings obtained
from this study will also provide indirect benefit to
through impact and potential improvement of treatment
norms and guidelines.
It is critical that all participants with positive syphilis
tests at any follow-up point be treated. At the time of
enrollment, participants will be asked to provide contact
information such as a name or nickname, address and
phone number, email address, and telephone number, as
well as the names and contact information for two
relatives or friends that will know their whereabouts,
although participants will not be excluded from the
study if they do not wish to provide additional contacts.
For positive test results obtained after point-of-care test-
ing and RPR titration (e.g. Western Blot and/or CT/NG
diagnosis), the study team will contact participants by
telephone or text message and set up an appointment
for results notification and no-cost treatmentor referral
to the Peruvian National HIV Treatment Program for
HIV treatment.
General findings and recommendations for changes in
STI management guidelines will be presented to, and
discussed with, two different constituencies: (a) a technical
group (other researchers, government officials, infectious
disease and sexual health specialists); and (b) a community
group (community advisory board and other community
representatives). A final version of recommendations will
be provided to key stakeholders, community members,
and the Ministry of Health of Peru. We will make great ef-
forts to identify feasible changes and produce concrete
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present syphilis management guidelines, particularly in
Peru. Our study will also have relevance to other Latin
American and lower-middle income countries, particu-
larly those with concentrated epidemics among high-risk
populations, such as MSM.
The information we intend to gather during the pro-
posed study has the potential to provide a more compre-
hensive and sound understanding of the syphilis epidemic,
including prevention, diagnosis, and treatment. Know-
ledge from the behavioral, diagnostic and molecular com-
ponents of our study will offer potential to develop new
approaches and inform efforts in syphilis control. Identifi-
cation of pathogen subtypes will provide researchers the
ability to distinguish intrinsic resistance and actual re-
infection. Insights from the immunologic study of cyto-
kines may provide new avenues in identifying potential
serologic markers for cure. Thus, our study will help ex-
pand the current clinical and public health response to
syphilis, which has proven insufficient in combating the
epidemic, with the goal of ultimately reducing the inci-
dence and prevalence of syphilis infection in Peru and
worldwide.
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